Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., ...
Mohali: An unpaved, badly damaged stretch of road in Phase 7 turned into a major traffic hazard after three two-wheeler ...
Falcon Heavy NROL-97 is set to launch October 1 from Kennedy Space Center, marking the first NRO classified payload ever ...
Navy autonomous warship program reaches its first production milestone: three Louisiana shipbuilders will build 30 medium ...
Primary composite endpoint met: 61% of patients achieved visual and pathological response across all treated lesions.Complete clinical and pathological response in 56% of high-risk head & neck ...
Eli Lilly's eloralintide plus low‑dose tirzepatide cut weight up to 23.3% and A1C by 2.9% in a 48‑week Phase 2, beating ...
The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of ...
SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports ...
Eli Lilly (LLY) and Viking Therapeutics (VKTX) delivered back-to-back clinical wins in the same week — one pushing the ...
LNG Canada’s joint venture partners have taken a final investment decision on Phase 2, locking in a second pair of ...
Hemab Therapeutics is building a hemostasis ladder, targeting ultra-rare to mass-market bleeding disorders, with a robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results